首页 | 本学科首页   官方微博 | 高级检索  
     

肿瘤坏死因子基因多态性与非霍奇金淋巴瘤临床与预后的相关研究*
引用本文:赵洪云,钟雪云,陈运贤. 肿瘤坏死因子基因多态性与非霍奇金淋巴瘤临床与预后的相关研究*[J]. 中国肿瘤临床, 2010, 37(1): 23-28. DOI: 10.3969/j.issn.1000-8179.2010.01.007
作者姓名:赵洪云  钟雪云  陈运贤
作者单位:华南肿瘤学国家重点实验室 中山大学肿瘤防治中心内科(广州市510060 )① 暨南大学医学院 ② 中山大学第一附属医院血液内科
摘    要:目的:探讨肿瘤坏死因子α(tumor necrosis factor alpha ,TNF-α)基因-308 位和淋巴毒素(Lymphotoxin-α ,LT α)基因+ 252 位基因多态性与非霍奇金淋巴瘤(NHL )临床及预后的关系。方法:采用聚合酶链式反应(PCR )、限制性内切酶消化及电泳技术,对中国广东省96例NHL 患者和72例正常对照者的TNF-α 和LT α 基因的单碱基突变多态性进行检测,收集其临床资料进行生存状况分析。结果:1)NHL 患者两位点联合单倍体分型在性别、年龄、分期等临床特征的分布无显著性差异;而联合单倍体分型的高危型在不同人群中有显著性差别(NHL 组70.4% ,对照组45.2% ,P=0.018),NHL 治疗不敏感组中高危型比例明显大于治疗敏感组,相对危险度为2.887(95%置信区间为1.188~7.016)。 2)Kaplan-Meier 方法进行生存分析,发现高危型与低危型的无瘤生存时间、总生存时间有显著性差异:高危型组平均生存时间为16.19个月,低危型组平均生存时间为48.63个月,1 年无瘤生存率分别为66.67% 、87.50%(P=0.023 1);2 年生存率分别为39.95% 、65.13% ,4 年生存率分别为8.32% 、46.52%(P=0.001 2);COX回归模型显示联合单倍体分型是影响预后的危险因素之一(P=0.034)。 结论:TNF-α-308 位和LT α + 252 位联合单倍体分型与中国广东省NHL 患者的治疗反应、生存等预后因素有关,可考虑将测定两位点多态性作为评估NHL 预后的一种敏感指标。 

关 键 词:非霍奇金淋巴瘤   肿瘤坏死因子   基因多态性
收稿时间:2009-04-02

Relationship of Tumor Necrosis Factor Genetic Polymorphisms with the Clinical Course and Outcome of Non-Hodgkin's Lymphoma
ZHAO Hongyun,ZHONG Xueyun,CHEN Yunxian. Relationship of Tumor Necrosis Factor Genetic Polymorphisms with the Clinical Course and Outcome of Non-Hodgkin's Lymphoma[J]. Chinese Journal of Clinical Oncology, 2010, 37(1): 23-28. DOI: 10.3969/j.issn.1000-8179.2010.01.007
Authors:ZHAO Hongyun  ZHONG Xueyun  CHEN Yunxian
Affiliation:1State Key Laboratory of Oncology in South China, Guangzhou 510060, China
Abstract:Objective:To investigate the relationship of-308bp polymorphism in tumor necrosis factor-α (TNFa)gene and+252bp in lymphotoxin-α(LTα)gene with the clinical course and outcome of non-Hodgkin's lymphoma(NHL).Methods:The single base change in TNFα gene and LTα gene was analyzed among 96 Chinese patients with NHL and 72 normal controls by using PCR-restrictive fragment length polymorphism (RFLP).The clinical data were collected and survival analysis was performed.Results:In NHL patients,no statistcally significant association was found between the presence of a given TNF/LT haplotype status and clinical variables such as age,seX,disease stage,and so on.The patients carrying low-risk haplotype achieved a more sensitive response to first-line therapy than that in patients with high-risk haplotype(70.4%v 45.2%:P=0.018).The estimated 1-year progression-free survival rates in the high-risk and low-risk groups were 66.67% and 87.5%,respectively(log-rank test,P=0.0231).Kaplan-Meier method showed that the estimated 2-year and 4-year overall survival rates were 39.95%and 8.32%in patents carrying high-risk haplotypes and 65.13%and 46.52%in patients carrying low-risk haplotypes,respectively(log-rank test,P=0.0012).In multivariate Cox regression models.the TNF/LT haplotype status was found to be a dsk factor for outcome of NHL (P=0.034).Conclusion:There is an association between TNF/LT haplotype status and response to therapy and outcomes of NHL in Canton area,China.Detecting TNF/LT haplotype may be a sensitive method to evaluate the outcome of NHL.
Keywords:Non-Hodgkin's lymphoma  Tumor necrosis factor  Gene polymorphism
本文献已被 万方数据 等数据库收录!
点击此处可从《中国肿瘤临床》浏览原始摘要信息
点击此处可从《中国肿瘤临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号